Return to program book search
Common Controversies in Dermatologic Drug Therapy
Open admission, no tuition or ticket.
Friday, August 17
2:00 PM - 5:00 PM
Stephen E. Wolverton, MD, FAAD
- Kenneth B. Gordon, MD, FAAD
- Julie Claire Harper, MD, FAAD
- Theodore Rosen, MD, FAAD
Following this course, the attendee should be able to:
- Make informed decisions concerning common controversies in dermatologic drug therapy.
- Evaluate controversies in future practice determining the pros, cons, and rationale for the most optimal clinical decisions.
This session is directed at clinicians who understand the need to be decisive with therapeutic controversies, even when data to make these decisions are not always complete. The triad of (1) literature support, (2) personal experience, and (3) biologic plausibility will guide decisions on various controversies. Topics discussed will include challenging decisions with antibacterials, hormonal contraceptives, isotretinoin, and various biologic therapeutic agents. Particular emphasis will be placed on the most worrisome potential adverse effects such as thromboembolism, carcinogenicity, opportunistic infections, and bacterial resistance.
|Friday, August 17|
|2:00 PM||Current controversies concerning antimicrobial resistance / Dr. Rosen|
|2:45 PM||Controversies concerning isotretinoin (IBD, depression) and hormonal contraceptives / Dr. Harper|
|3:30 PM||Difficult decisions and concerns with biologic therapeutic agents / Dr. Gordon|
|4:15 PM||Brand new controversies involving drug safety, including medicolegal concerns / Dr. Wolverton|